Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
OBJECTIVE
To assess tumor necrosis factor-α (TNF-α), infliximab (IFX) concentrations, and antibodies against IFX molecules in patients with inflammatory bowel disease (IBD) who develop loss of response, side effects, or allergic reaction during anti TNF-α therapy.


METHODS
Blood samples of 36 patients with response loss, side effects, or hypersensitivity to IFX therapy (Group I) and 31 patients in complete clinical remission (Group II) selected as a control group were collected to measure trough serum TNF-α level, IFX, and anti-IFX antibody (ATI) concentration. We examined the correlation between loss of response, the development of side effects or hypersensitivity, and serum TNF-α, IFX trough levels, and ATI concentrations.


RESULTS
The serum TNF-α level was shown to be correlated with the presence of ATI; ATI positivity was significantly correlated with low trough levels of IFX. ATIs were detected in 25% of IBD patients with loss of response, side effects, or hypersensitivity, however no association was revealed between these patients and antibody positivity or lower serum IFX levels. Previous use of IFX correlated with the development of ATI, although concomitant immunosuppression did not have any impact on them.


CONCLUSIONS
On the basis of the present study, we suggest that the simultaneous measurement of serum TNF-α level, serum anti TNF-α concentration, and antibodies against anti TNF-α may further help to optimize the therapy in critical situations.
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Éva
É
Pallagi-Kunstár
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Klaudia
K
Farkas
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Zoltán
Z
Szepes
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Ferenc
F
Nagy
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Mónika
M
Szűcs
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Róbert
R
Kui
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Rolland
R
Gyulai
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Anita
A
Bálint
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Tibor
T
Wittmann
Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Anita Bálint, Tibor Wittmann, Tamás Molnár, First Department of Medicine, University of Szeged, H6720 Szeged, Hungary.
Tamás
T
Molnár
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D000906:Antibodies / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004342:Drug Hypersensitivity / Q000097:blood / Q000209:etiology* / Q000276:immunology; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012074:Remission Induction; D012307:Risk Factors; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000906:Antibodies; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
Antibody; Inflammatory bowel disease; Infliximab; Tumor necrosis factor-α